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INTRODUCTION 
 Tuberculosis continues to be a major public health problem in 
India. 30 percent of the population are infected with tubercle bacilli (4). 
The factors attributed for this are poor quality of life, poor housing, 
overcrowding, population explosion, undernutrition, lack of education, 
large families, early marriage, lack of awareness. 
 Added to these factors is the increasing incidence of HIV 
infection in developing countries. As HIV infection decreases cell 
mediated immunity, it predisposes to active tuberculosis in previously 
infected people. So HIV infection can increase the morbidity and 
mortality due to active tuberculosis and the socio economic burden. 
 Even in developed countries where tuberculosis was under 
control, with increasing incidence of HIV infection there is resurgence 
of tuberculosis. 
 Tuberculosis appears early in the course of HIV infection before 
the appearance of other manifestations of the disease and opportunistic 
infections. so the center for disease control, has advised to screen all 
tuberculosis patients for HIV confection. 
 In developing countries like India, where tuberculosis is endemic 
whether the same rule has to be followed remains unanswered. Studies 
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done in various parts of the country regarding seroprevalence of HIV 
infection shows prevalence ranging from 1% to 10%. The  factors which 
predict the HIV co-infection in tuberculosis patients are also not clearly 
known. 
 Approximately one third of the 36 million HIV infected persons 
in the world are co-infected with M.Tuberculosis. 75% of these people 
reside in sub-Saharan Africa patients with HIV are at greater risk of 
reactivating latent infection (7-10% annual risk compared to 5-10% 
lifetime risk in an HIV - uninfected individual), of acquiring TB from an 
open contact (10-20% compared to 5-10%), of developing progressive 
primary disease (30-40% compared to 5-10%) and of developing 
disseminated, miliary on extrapulmonary disease (>60% compared to 
<25%) 
 The purpose of the study is to find out the seroprevalence of HIV 
infection in tuberculosis patients and to find out the predictors of HIV 
co-infection. 
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OBJECTIVES OF THE STUDY 
1. To find out the seroprevalnece of HIV infection in 
Tuberculosis patients (Pulmonary and extrapulmonary) 
admitted in Govt. General Hospital, Chennai. 
2. Ton find out the factors associated with HIV co-infection in 
Tuberculosis patients. 
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REVIEW OF LITERATURE 
HISTORY OF TUBERCULOSIS 
 Tuberculosis is undoubtedly an ancient disease. Indeed, Man may 
have been affected by it ever since he evolved, as a species on this 
planet. Evidence of existence of tuberculosis has been found in the 
bones of prehistoric man, found in Germany & Egypt. (2500-1000 B.C.) 
(31). Description of what could be tuberculosis has also been noted in 
the ancient Hindu and Chinese writings. Hippocrates (460-377 B.C) also 
devoted some attention to tuberculosis. However he felt that attention to 
tuberculosis was a waste of time and such cases were a burden on the 
state. 
 The theory that tuberculosis is an infectious disease was 
conceived by Aristotle more than 2000 years before the discovery of 
tubercle bacillus. Villemin demonstrated in a series of classical 
experiments that tuberculosis is caused by a specific agent and that it 
can be transmitted from man to animals by inoculation of infected 
material (1865).Robert  Koch applied himself to this task and in 1882 
this elusive microbe was identified. Laennec in 1819 invented the 
stethoscope and described auscultation. Laennec and Bayle described 
the tubercles and added new knowledge, Rudolph Virchow, the founder 
of cellular pathology, described the development of caseation in 
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tuberculous tissue. In 1890, Koch produced tuberculin and described 
Koch's phenomenon. X-rays, discovered by Roentgen in 1895 were put 
into clinical use by 1904 and helped in diagnosis of pulmonary 
Tuberculosis. Calmette and Guerin produced alternated Bovine Bacillus 
after subculturing about two hundred and thirty time from 1908 till 
1921. 
HISTORY OF HUMAN IMMUNODEFICIENCY VIRUS 
 The Acquired Immune Deficiency Syndrome (AIDS) was first 
recognised in the United States in the summer of 1981, when the Center 
for Disease Control and Prevention (CDC) reported the unexplained 
occurrence of pneumocystis carinii pneumonia in five previously 
healthy homosexual men in Los Angeles and of Kaposi's sarcoma in 26 
previously healthy homosexual men in New York and Los Angeles (3). 
Within months it was recognised in injection drug users (IDUs) and 
soon thereafter in recipients of blood transfusions and in haemophiliacs. 
Because of the disproportionate number of cases of AIDS among 
Haitians in the United States early in the epidemic, this group was 
incorrectly designated as a 'risk' group. As the epidemiological pattern 
of the disease unfolded, it became clear that a microbe transmissible by 
sexual contact and blood or blood products was the most likely etiologic 
agent of the epidemic. 
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 In 1983, Human Immunodeficiency virus as isolated from a 
patient with lymphadenopathy, and by 1984 it was demonstrated clearly 
to be the causative agent of AIDS(3). The virus, which belongs to the 
lentivirus subfamily of the large family of retroviruses (Retroviridae) 
was formerly called lymphadenopathy associated virus (LAV), Human 
T lymphotropic virus (HTLV) type III and AIDS associated retrovirus 
(ARV). In 1985, a sensitive enzyme linked immunosorbent assay 
(ELISA) was developed (3). Seroprevalence studies when combined 
with monitoring of CD4 + T Cell counts as a parameter of 
immunosuppression, led to the realisation of the global pandemic of 
AIDS and that there is a broad spectrum of HIV disease ranging from 
asymptomatic infection and clinical latency to advanced clinical disease, 
the latter constituting AIDS. Today, it is clear that virtually every 
practicing physician in the country and worldwide will be required to 
have some degree of familiarity with the workup, diagnosis, 
management and specific treatment of HIV infect individuals. 
 Sequence Analysis has led to the estimate that HIV 1 was 
introduced into humans in the early 1930s. 
 Since 1981 AIDS has grown to be the second leading cause of 
death in Africa. (Accounting for over 20% of deaths). It is now 
recognised that the immune deficiency is a consequence of continuos 
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high level HIV replication leading to virus and immune mediated 
destruction of the key immune effector cell, the CD4 Lymphocyte. 
HUMAN IMMUNODEFICIENCY VIRUS 
 The four recognised human retrovirus belong to two district 
groups. The human T lymphotropic viruses, HTLV I and HTLV II 
which are transforming retroviruses, and the Human Immunodeficiency 
Viruses, HIV 1 and HIV 2 which are cytopathic viruses. The most 
common cause of HIV disease throughout the world is HIV 1. HIV 2 
was first identified in 1986 in West African patients and was originally 
confined to West Africa. 
 Each mature virion is spherical in shape it has a lipid membrane 
lined by a matrix protein and studded with glycoprotein gp 120 and gp 
41 spikes surrounding a cone shaped protein core. This core houses two 
copies of the ssRNA genome and viral enzymes. The virus infects the 
CD4 cell in a complicated sequence of events involving initial 
attachment and receptor engagement through the viral gp 120 and the 
CD4 cell receptor. Other cell expressing the CD4 cell receptor and 
permissive to infection are monocytes and macrophages, follicular 
dendritic cells and microglial cells in the central nervous system. HIV 
can also infect astrocytes through CD4 cell receptor independent 
attachment and fusion involving the chemokine receptor CXCR4. 
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 It has been calculated that each day more than 1010 virions are 
produced and 109 CD4 cells destroyed. This represents a turnover of 
30% of the total viral burden and 6-7% of the total body CD4 cells 
daily. A small percentage of T cells (<0.01%) enter a post - integration 
latent phase and represent the main reservoir of HIV within these cells 
there is ongoing low - level replication even when plasma levels of HIV 
are below the levels of detection as a result of antiretroviral treatment. 
They are important as sanctuary sites from anti viral therapy, continuing 
sources of virus. 
 On the basis of DNA sequencing HIV - 1 can be subdivided into 
group M (major world wide distribution) group O (coutlier, restricted to 
West Africa and divergent from group M) and group N (rare and highly 
divergent). Group M and O can be subdivided further into subtypes. 
There are 10 subtypes for group M lettered A-K. Subtype B 
predominates in North America. Australia and Europe, Subtype A in 
Africa, subtype C in South Africa and India and subtype E in Thailand. 
 HIV - 2 in an important, but separate retrovirus occurring in West 
Africa or countries with ties to the region and has at least five subtypes. 
The virus differs from HIV - 1, in the patients have lower viral loads, 
slower CD4 decline, Lower rates of vertical transmission and slower 
progression to AIDS (12 fold lower). 
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TRANSMISSION 
 1. Sexual :  HIV infection is predominantly a sexually 
transmitted disease worldwide. Although more than 50% of case are due 
to homosexual transmission, heterosexual transmission is clearly the 
most common mode of infection world wide, particularly in developing 
countries (3). 
 The receiving partner is at a greater risk than the insertive 
partners, in both vaginal and anal intercourse. 
 There is approximately a 20-fold greater chance of transmission 
of HIV from a man to woman than from a woman to a man through 
vaginal intercourse (3), because female is the recipient partner in sexual 
intercourse, and due to various well known anatomical, biological and 
serological reasons. 
 2. Blood and Blood Products : HIV can be transmitted by blood 
and blood products, both among individual who share contaminated 
paraphernalia (needles and syringes) for injection drug use and in those 
who receive transfusion of blood and blood products. Hyperimmune 
gamma globulin, hepatitis B immunogolobulin, plasma derived hepatitis 
B vaccine and Rho immune globulin have not been associated with 
transmission of HIV infection (3). The procedures involved in 
processing the products either inactivate or remove the virus. 
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 3. Occupational : The risk of HIV transmission following skin 
puncture from a needle or a sharp object that was contaminated with 
blood from a person with documented HIV infection is approximately 
0.3 percent (3). The risk increases for exposures to blood from patients 
with advanced stage of disease, probably owing to the higher titer of 
HIV in the blood as well as to other factor such as the presence of more 
virulent strains of virus. 
 The risk associated with mucocutaneous exposure is 0.1%. 
Transmission of HIV through intact skin has not been documented. The 
risk of transmission from an infected health care worker to patients is 
extremely low. 
 4. Maternal-fetal transmission : HIV can be transmitted from 
mother to her fetus during pregnancy or delivery. This is an extremely 
important mode of transmission in developing countries where the 
proportion of infect women to men is  approximately 1:1 (3). This 
occurs most commonly in the perinatal period. Factors associated with 
higher risk are advanced disease, low CD4 + T cell count, high level of 
viremia, Vit A deficiency, chorioamnitis and funisitis and acute primary 
HIV infection during pregnancy. Postnatal transmission through 
colostrum and breast milk has also been clearly documented. Risk 
attributable to breast feeding 7 to 22 percent. 
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 Although virus can be identified from virtually every body fluid, 
there is no evidence that HIV transmission can occur as a result of 
exposure to tears, sweat and urine (3). 
S.No. Modes of Transmission Efficacy Source of infection 
1. Sexual intercoruse 0.1 - 1.0% 80 - 86% 
2. Blood transfusion 90 - 95% 3 - 5 % 
3. Perinatal 20 - 40 % 2 - 3 % 
4. Injectable drug users 0.5 - 1.0% 3 - 5% 
5. Needle Stick exposure < 0.1%  
 
TUBERCULOSIS : PROBLEM STATEMENT 
World 
 Using the trends in case notification it is estimated that there were 
8.8 million new cases of Tuberculosis in 2002 of which 3.9 million were 
smear positive. The global incidence rate of tuberculosis (percapita) is 
growing at approximately 1.1 percent per year and the number of cases 
at 2.4 percent per year. During 2002 about 1.56 million people died of 
this disease and global burden of disease in terms of DALYS lost was 
about 34.73 million. According to WHO estimates there were 16-20 
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million cases of Tuberculosis worldwide in 2001. The global incidence 
rate of for Tuberculosis being 119 per lakh population with low income 
countries carrying most of the burden with the incidence rate of 197 per 
lakh population. Middle income countries are having the rate of about 
85 per lakh population, and high income countries about 9 per lakh 
population. 
 It is estimated that estimated that about one-third of current global 
population is infected asymptomatically with tuberculosis of whom 5-10 
percent will develop clinical disease during their Life Time. 
 Eight out of Ten of all those struck by Tuberculosis are in 
economically productive age group of 15-49 years. It kills more adults 
than any other infectious disease. The South East Asia Region countries 
carry 38 percent of global burden of tuberculosis with 3 million new 
cases and nearly 0.6 million deaths occuring every year. 
HIV PROBLEM STATEMENT 
World 
 According to the recent estimates, by the end of 2004, 25 million 
people had already died of AIDS. Counting both those who have died 
and those currently living with virus in the past 20 years 65 million 
people have been infected. AIDS had orphaned more than 13 million 
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children worldwide. In south and south east Asia and the pacific about 
6.1 million adults and 800,000 children were newly infected with the 
adult prevalence of 0.6%. 
 Global notes of HIV / AIDS epidemic December 2004. 
Total  4.9 million 
Adults  4.3 million 
People newly infected with 
HIV in 2004 
Children < 15 years 640000 
Total  39.4 million 
Adults  37.2 million 
Number of people living with 
HIV / AIDS 
Children < 15 years 2.2 million 
Total  3.1 million 
Adults  2.6 million AIDS deaths during 2004 
Children < 15 years 510000 
Total number of AIDS orphans since the beginning of 
the epidemic 
13.2 million 
 
 Trends in AIDS incidence show important difference between 
regions of the world. More than 95% of new cases remain in developing 
counties. In Africa, HIV infection in women now out-number those in 
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men. The number of AIDS deaths in industrialised countries has 
recently been falling due to combined antiretroviral therapies. In South - 
East Asia Region, the number of reported cases continue to increase and 
is likely to do so well into the early part of 21st Century. India, 
Thailand, Myanmar report the majority of cases with HIV/AIDS in the 
region. 91% are in the age group of 15-49 yrs and 4.6% are children. 
The male to female ration is 4 to 1. Heterosexual contact is the 
predominant mode of spread (85%) followed by injection drug use (7%) 
and mother to child transmission (5%). 
Regional HIV /AIDS statistics and features, December 2003. 
Region 
Adults and 
children 
living with 
HIV/AIDS 
Adults and 
children Newly 
infected with 
HIV in 2003 
Adults 
Prevalence 
Rate 
Sub-Saharan Africa 26.6.million 3.2 million 8.0% 
North Africa and 
middle East 
600,00 55000 0.3% 
South and southeast 
Asia 
6.4 million 855000 0.6% 
East Asia and pacific 1.0 million 210000 0.1% 
Latin America 1.6 million 150000 0.6% 
Caribbean 470000 62500 2.5% 
Eastern Europe and 
Central Asia 
1.5 million 230000 0.7% 
Western Europe 600000 35000 0.3% 
North America 995000 45000 0.65 
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Australia and New 
Zealand 
15000 850 0.1% 
Total 40 million 5 million 1.1% 
 
Source : Joint united Nations programme on HIV/AIDS (UN AIDS) 
India 
 India's epidemic seems to be following the so called type 4 
pattern, first described in Thailand. the epidemic shifts from the highest 
risk group (Commercial sex workers, drug users) to bridge population 
(clients of sex workers, STD patients and partners of drug users) and 
then to general pouplation. 
 HIV estimates for the year 2004 have been worked out to be 
5.134 million HIV infections in the adults population (15-49 years age 
group in the country). These estimate have been pegged up for 20% as 
range (as in previous years) to take care of unaccounted  number of high 
risk groups and other age groups to provide upper range as 5.1 million 
HIV infections. 
 The cumulative number of AIDS cases reported as on July 2005 is 
1,11,608 out of which 89% of cases, are in the age group of 15 to 44 
years, the economically productive age group. Out of the total AIDS 
cases reported 73% are men and 27% are women. 
 16
 One of the characteristic features of Indian HIV scenario is its 
heterogeneously. While the whole country is afflicted with HIV 
infection, its prevalence various from state - to state. The most populous 
states of India are least affected for e.g. Uttarpradesh, Bihar Rajasthan, 
Madhya Pradesh, Orissa etc., while state like Maharastra, Tamilnadu, 
Karnataka Andrapradesh, Manipur and Nagaland are the most affected. 
In these stated HIV infection has even percolated into the general 
population leading to intense mother to child transmission of HIV. 
 The states will be categorized as high, moderate or low based one 
following definition. 
 High prevalent states: 
States where HIV prevalence in antenatal women is 1% or more 
 Moderate prevalent states: 
States where the HIV prevalence in antenatal women is less than 
1% and prevalence is STD and other high risk groups is 5% or 
more 
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Low Prevalent States 
 States where the HIV prevalence in antenatal women is less than 
1% and HIV prevalence among STD and other high risk group is less 
than 5%. 
Group I (High prevalence states) 
 Includes states like Maharashtra, Karnataka, Andra Pradesh, 
Manipur, Mizoram, Nagaland and Dader and Nager Haveli where HIV 
infection has crossed 1% or more in antenatal mother. ANC prevalence 
in Tamilnadu has come down to 0.63 in 2004 from 1.13 in 2001. 
Group II (Moderate prevalence states) 
 Included state like Gujarat, Kerala, Rajasthan and Goa where HIV 
infection has crossed 5% or more among high risk group but the 
infection is below 1% in Antenatal mothers. 
Group III (Low prevalence states) 
 Includes remaining states where the HIV infection in any of the 
high risk group is still less than 5% and is less than 1% among antenatal 
mothers. 
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 The high risk group of population includes patients attending STI 
clinics and intravenous drug uses while low risk of population including 
mothers attending antenatal clinics. 
 The epidemic in Tamilnadu has clearly shifted from high risk 
groups to general population. It reflects the percolation of the infection 
to general population. 
HIV PREVALENCE IN RELATION TO TUBERCULOSIS 
 In 1988, A systematic nationwide sampling of HIV infection 
prevalence was undertaken by the Centre for Disease Control (CDC). 
The median seropositivity rate in 4301 persons with Tuberculosis was 
3.4%. The rates varied widely (from 0% to 46%) among clinics. The 
highest rate was reported from New York City (46%) followed by New 
York (34%), Boston (27%), Miami (24), Baltimore (13%). A similar 
study in 1990 showed a seropositivity rate of 7.5%. In 1991 it was 9.5%. 
The overall seroprevalence rate in these areas was 13% in 1989, 18% in 
1990, and 21% in 1991. Among Asians the HIV prevalence was less 
than 1% throughout the period. 
 Kenya : 50% in districts with an early increase in notification 
rates and 29% in the other study districts (18). 
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 In the Hlabisa district Tuberculosis programme, South Africa, the 
prevalence of human immunodeficiency virus infection among adults 
with Tuberclosis increased from 36.0 in 1993 to 65.9 in 1997 (29). 
 The WHO has estimated that worldwide there are probably 
approximately 10 million persons who are infected with both M. 
tuberculosis and HIV, nearly 80% of them being in Africa. The 
prevalence of HIV among Tuberculosis patients in Sub-Saharan African 
countries ranged from 20% to 67%. 
INDIA 
 An increase in HIV prevalance represents a serious threat to 
tuberculosis control in India current estimates suggest that nearly 4.56 
million persons in India are infected with HIV and that approximately 
1.64 million of these individuals are also infected with tuberculosis. An 
additional 1,40,000 TB cases can be expected annually among 
tuberculin skin-Test positive HIV infected individuals - as per 
Government of India (2004) Annual Report 2003-04 ministry of Health 
and family welfare, New Delhi. 
 Department of pediatrics, Jawaharlal Nehru Medical College, 
AMU, Aligarh, UP India conducted study in 2000 showed a 
seroprevalance rate of 2% among children below 12 years of age with 
pulmonary and extrapulmonary tuberculosis. 
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 Department of Medicine All India Institute of Medical Sciences, 
Ansari Nagar, New Delhi India conducted study - the HIV seropositivity 
among adult TB patients from AIIMS between 2000-2002. The 
seropositive in adult TB patients was 9.4%. 
 Tuberculosis Research Centre IC MR Chennai India conducted 
study to estimate seroprevalence of human immuno deficiency 
virus(HIV) infection among tuberculosis patients in Tamilnadu. The 
study was under taken in four centres district tuberculosis centre (DTC) 
Vellore, Tuberculosis sanatorium Pennathur (Vellore) District TB centre 
(DTC) Kancheepuram and the Govt. Thiruvotteswarar Tuberculosis 
Hospital (GTTH), Chennai in the northern part of Tamilnadu during 
1998. Results: The over all HIV seroprevlance among TB patients was 
4.7 percent. The highest HIV seropositivity rate was found among 
patients aged 30-39 years (10.6%) Sputum smear positively was 88 
percent among the HIV negative and 83 percent among HIV positive 
tuberculosis patients. 
 Rajan Babu TB Hospital and infectious diseases hospital GTB 
Nagar Delhi conducted study-clinical profile of tuberculosis in patients 
with HIV infection / AIDS. The most common symptom in these 
patients was cough and expectoration, followed by fever and weight 
loss. Acid fast Bacilli AFB smear positivity was found in 21.4% 
patients. On chest skiagram, infiltrative lesions were commonly seen in 
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61.9% patients. Extra pulmonary tubercular manifestations were seen in 
45.6% HIV / TB cases. 
 Similar study conducted by the AIDS cell, Institute of 
Mcirobiology, Madras Medical College, Madras from January 1991 to 
May 1993, Showed a rise from 0.77% in 1991 to 3.4% in 1993 (17). 
 A similar study conducted at Institute of Thoracic Medicine, 
Chetpet, Chennai in 1997 showed an incidence of 4% of HIV positivity 
among Pulmonary Tubeculosis Patients. 
 A similar study conducted at Govt. Hospital for Thoracic 
Medicine, Tambaram, showed an incidence of 9.6% in 2000(33). 
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MATERIALS AND METHODS 
STUDY DESIGN 
 Cross sectional study of one hundred tuberculosis patients. 
STUDY POPULATION 
 Patients admitted with suspected Tuberculosis in General Medical 
wards Govt. General Hospital, Chennai. 
INCLUSION CRITERIA 
1. Patients who have radiological or bacteriological evidence 
of active Pulmonary Tuberculosis. 
2. Meningitis patients with CSF analysis suggestive of 
Tuberculous meningitis. 
3. Patients with exudative ascites with laparoscopic evidence 
of peritoneal Tuberculosis. 
4. Histologically proved tuberculous lymphadenitis patients. 
EXCLUSION CRITERIA 
1. Old inactive pulmonary tuberculosis patients 
2.  Patients whose HIV status is already known. 
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STUDY DURATION 
 October 2005 to January 2006. 
 The study was initiated in October 2005 for the purpose of finding 
the prevalence of HIV infection among tuberculosis patients and the 
factors associated with HIV infection in tuberculosis patients. One 
hundred tuberculosis patients admitted in general medicine wards were 
studied. 
 Detailed history was taken and physical examination done for 
each patient as shown in proforma. 
 All patients underwent the following investigations. 
1. Complete Hemogram : TC, DC, ESR, Hb% 
2. Chest X-ray PA View : This was taken at Radiology 
department, Govt. General Hospital and reported by two 
doctors independently. 
3. Mantoux test : 
0.1 ml of purified protein derivative (PPD) of the strain RT 23 
containing 1 tuberculin unit is injected intradermaly into the forearm of 
patients and a wheal is raised. Results are read after 48 hrs. An 
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induration with horizontal diameter of more than 10 mm is taken as 
positive for non HIV patients and induration of more than 5 mm is taken 
as positive for HIV positive patients. 
SPUTUM AFB 
 Sputum is collected in sterile test tubes on three consecutive days 
and stained with Ziehl - Neelsen technique (Carbol fuchsin, Loeffler's 
Methylene blue) and the slide were screened by microbiologist for he 
presence of Acid fast Bacilli. 
 Apart from these investigations, 
 Pleural fluid analysis, ascitic fluid analysis, Cerebrospinal fluid 
analysis were done for cell count, Cytology, AFB, Protein if necessary 
to demonstrate tuberculous etiology. 
SCREENING FOR HIV ANTIBODIES 
 Counselling 
 The center for Disease Control (CDC) has published 
recommendations for HIV testing and counselling. Testing for evidence 
of HIV infection should always be accompanied by pre and post test 
counselling. The counsellor should be knowledgeable about this process. 
Because results of tests for HIV infection have profound consequences 
 25
and raise many questions, persons should given written informed 
consent for the testing procedure and should understand the choices 
implied by the test results(1). 
 Counselling should include information about the test, HIV 
infection and AIDS as well as risk behaviours associated with the 
transmission of HIV. Discussion should also include the consequences 
of a positive or negative result for the person being tested (Medical care, 
Pregnancy, Employment, insurance) and other (family, lovers, friends) 
as well as the need for appropriate followup in the event of postive test 
results. Explanation of equivocal results that require additional tests may 
be necessary. Even for a person whose result is negative, counselling is 
recommended to allay a false sense of security and to promote future 
risk reduction behaviours. If the clinical suspicion of infection is high, 
based on risk behaviour or symptoms, follow up testing should be 
recommended. In the case of suspected primary infection, referral 
should be made to a research site or a knowledgeable HIV healthcare 
provider even if the antibody test is negative(1). 
 All the patients included in the study underwent pre and post test 
counselling. 
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SCREENING TESTS USED FOR HIV INFECTION 
Enzyme linked Immunosorbent Assay 
 Most commonly used test because of their relatively simple 
methodology, inherent high sensitivity as well as specificity and 
suitability for testing large numbers of samples particularly in blood 
testing centers. The most popular ELISA involves an indirect method in 
which antibody in serum of the patient is allowed to react with HIV 
antigen attached to a well of a 96 well microtiter plate or to a 
macroscopic beed that subsequently is placed  in a plate well. The test 
kits used in the study are LAB SYSTEMS and DETECT-HIV. 
Rapid Test 
These can be performed in less than 30 minutes. When performed 
correctly, rapid HIV assays are accurate. They are easy to perform and 
have utility in developing countries where facilities may not be optimal, 
stable electricity may be unavailable and formal education programme 
for laboratories are absent. They produce a well - circumscribed colored 
dot on the solid phase surface if the test is positive. The test kits used in 
the study are Tridot and Immunocomb (Bispot) where both HIV I and 
HIV II can be detected. 
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STRATEGIES OF HIV TESTING IN INDIA (30) 
 WHO / GOI have evolved strategies to detect HIV infection in 
different population groups and to fulfill different objectives. The 
various strategies, so designated, involve the use of categories of tests in 
various permutations and combinations. 
1. ELISA /Simple /Rapid tests (E/R/S) used in strategy, I, II & 
III. 
2. Supplemental test like Western Blot and line immunoassay 
are used in problem cases. e.g. in cases of indeterminate / 
discordant results of E/R/S. 
UNAIDS and WHO Recommendations for HIV Testing Strategies 
According to Test Objective and Prevalence of Infection in the 
Sample Population 
Objective of testing Prevalence of infection 
Testing 
Strategy 
Transfusion / Transplant safety All prevalence I 
Surveillance > 10% 
< 10% 
I 
II 
Diagnosis: Clinical 
signs/Symptoms of HIV 
infection  
> 30% 
< 30% 
I 
II 
Asymptmatic > 10% 
< 10% 
II 
III 
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STRATEGY I 
 Serum is subjected once to E/R/S for HIV. If negative, the serum 
is to be considered free of HIV and if positive, the sample is taken as 
HIV infected for all practical purposes. This strategy is used for 
ensuring donation safety (blood/blood products/organ, tissue, sperms 
etc). The unit of blood tested reactive (positive) is discarded. Donar is 
not informed. 
STRATEGY II 
 A serum sample is considered negative for HIV if the first ELISA 
report is so, but if reactive, it is subjected to a second ELISA which 
utilises a system different from the first one. It is reported reactive only 
if the second ELISA confirms the report of the first. This strategy is 
used for surveillance and for diagnosis only if some AIDS indicator 
disease is present. 
STRATEGY III 
 It is similar to strategy II, with the added confirmation of a third 
reactive ELISA test being required for a sample to be reported HIV 
positive. The test to be utilized for the first ELISA is one with the 
highest sensitivity and for the second and third ELISAs tests with 
highest specificity are to be used. 
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 All the patients included in the study were screened for HIV with 
ELISA. If it is reactive it is confirmed with another ELISA of different 
system and rapid test. It all are positive the patient is considered to be 
HIV positive. 
LIMITATIONS OF THE STUDY 
 Tuberculosis patients who were sick enough to be admitted in 
hospital only were included in the study. Patients whose general 
condition is satisfactory and treated as outpatient were not included in 
the study. 
ETHICAL ISSUES INVOLVED IN THE STUDY 
 Decisions about medical care, pregnancy, sexual and injection 
drug use behaviours and career planning can be affected by the results of 
an HIV antibody test. The risk that HIV test results may become known 
must be recognised by testing counsellors, clinicians, public health 
policy makers and above all persons who are considering being tested. 
Unfortunately persons with HIV confront fear and pain from knowing 
they are infected and serious social, financial and emotional problems 
resulting from individual and institutional prejudices about people with 
HIV and AIDS. 
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 Eviction, job loss, inability to buy or maintain health or life 
insurance and abandonment by family and friends are examples of some 
of the unfortunate consequences of being labeled as infected with the 
HIV virus. These events are not rare and can occur whenever 
confidentiality is violated or test results are requested by and released to 
employees, insurance companies or other individuals and groups. 
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RESULTS 
Out to hundred patients studied 62 are male and 38 are female. 
The age distribution of the patients are as follows: 
Age group No. of Patients 
11-20 07 
21-30 27 
31-40 27 
41-50 19 
51-60 16 
61-70 4 
 
  Married - 73 
  Unmarried - 27 
  Ratio  - 2.7:1 
CXR IN HIV POSITIVE CASES 
 Bilateral Diffuse infiltrates - 4 
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 Right sided pleural effusion - 1 
Right upper zone cavity with  
Bilateral midzone infiltrates - 1 
SPUTUM AFB 
Sputum AFB Positive Negative 
HIV Negative 28 66 
HIV Positive 1 5 
Total 30 70 
 
MANTOUX TEST 
Mantoux Positive Negative 
HIV Negative 43 51 
HIV Positive 0 6 
Total 43 57 
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DIAGNOSIS IN HIV POSITIVE CASES 
 Bilateral Pulmonary Tuberculosis : 5 
 Right tuberculous pleural effusion : 1 
DIAGNOSIS IN ALL CASES 
 Pulmonary Tuberculosis    : 66 
 Pleural effusion     : 11 
 Pneumothorax     : 01 
 Abdominal Tuberculosis    : 03 
 Tuberculous Meningitis    : 01 
 Miliary tuberculosis    : 04 
 Spinal Tuberculosis    : 01 
 Pulmonary tuberculosis with  
Pleural Effusion     : 07 
 Pulmonary tuberculosis with Meningitis  : 02 
 Pulmonary tuberculosis with Lymphadenitis : 02 
 34
 Pleural effusion with Meningitis  : 01 
 Tuberculous Meningitis with Tuberculoma : 01 
MODE OF TRANSMISSION IN HIV POSITIVE CASES 
 Sexual      : 6 
 Blood transfusion     : Nil 
 Hospital acquired     : Nil 
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DISCUSSION 
 In this study 6 out of 100 Tuberculosis patients were HIV 
positive. 
 All the HIV positive patients comes under the age groups 25 to 
40. Only one was above 35 and rest were between 25-35. 
 Five of them are males and one is female. All of them were 
married. 
 The study conducted by Department of Medicine, All India 
Institute of Medical Sciences Ansari Nagar, New Delhi, India to identify 
HIV seropositivity among adult tuberculosis patients in Delhi between 
2000-2002. Of the 555 patients with various forms of Tuberculosis 52 
were found to be seropositive (9.4%). Another study conducted by 
Department of Experimental Medicine, Tamilnadu Dr.MGR Medical 
University, Madras where well documented 112 pulmonary 
Tuberculosis patients were studied for the prevalance of HIV 
seropositivity by using two antibody screening tests along with western 
blot test. Ninteen of the pulmonary Tuberculosis patients were HIV 
seropositive (16.96%). 
 In our study 6 out of 100 Tuberculosis patients were HIV positive 
(6%). 
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 Tuberculosis Research Centre (ICMR) Chennai India conducted 
study as seroprevalance of human Immunodeficiency virus infection 
among Tuberculosis patients in Tamilnadu. The study was undertaken in 
four centres. District Tuberculosis Centre (DTC) Vellore, Tuberculosis 
Sanatorium Pennathur (Vellore), District TB Centre (DTC), 
Kancheepuram and the Government Thiruvotteswarar Tuberculosis 
Hospital (GTTH), Chennai in the northern part of Tamilnadu during 
1997-1998. A total of 2361 newly diagnosed TB patients were 
registered in this study. HIV serology after pre-Test counselling was 
done along with sputum examination for acid positive bacillus by smear 
for all patients. The overall HIV seroprevalence among TB patient was 
4.7 percent. In our study it was 6%. 
 The highest HIV seropositivity rate was found among patients 
aged 30-39 years (10.6%) in above ICMR study. In our study all the 
HIV positive patients comes under the age Groups between 25 to 35 
except only one patient was above 35. 
 In above ICMR study sputum smear positivity was 88 percent 
among the HIV negative and 83% percent among HIV positive patients 
and concluded that Acid - fast smear microscopy is adequate for the 
diagnosis of Pulmonary Tuberculosis. But in our study, Among total 94 
HIV negative patients, 81 patients having pulmonary disease, 28 
patients were sputum AFB positive. Among 6 HIV positive patients, 5 
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patients having pulmonary disease, and only one patient was sputum 
AFB positive. From our study HIV positive people with pulmonary 
tuberculosis may have a higher frequency of negative sputum smears in 
advanced state of HIV infection. So confirming the diagnosis may 
require sputum culture. 
 The tuberculin skin test often fails to work in people who are HIV 
positive because it relies on measuring the response of a person's 
immune system. If the immune system has been damaged by HIV, it 
may not respond even though the person is infected with Tuberculosis 
therefore have a higher frequency of false negative tuberculin skin tests 
results. 
 Department of TB diseases, KG Medical University CSM 
Medical University, Lucknow, India conducted study to determine the 
prevalance of human immunodeficiency virus infection among 
tuberculosis patients and to compare the clinico-radiological spectrum of 
tuberculosis tuberculosis among HIV seropositive and sero-negative 
patients was carried out. A total of 1105 Radiologically and or 
bacteriologically confirmed patients of tuberculosis were screened for 
HIV infection during the years 1995 to 1997 and from 2000-01. 
 Out of a total 1105 patients screened 31 (2.8%) were found to be 
HIV seropositive. Tuberculin positivity was less among HIV 
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seropositive patients as compared to HIV seronegative patients (22.6% 
vs 76.4%) p<0.001. 
 But in our study among 94 HIV seronegative patients 43 patients 
having Tuberculin skin test positive (45%), none of HIV positive 
having tuberculin test positive (0%). 
 Above CSM Medical University study, Among HIV seropositive 
patients mid and lower zone involvement, exudative lesions and 
mediastinal lymphadenopathy was more common as compared to 
seronegative patients, they concluded that the presentation of 
Tuberculosis was more often atypical among these patients. Another 
study Rajan Babu T.B. Hospital and infectious Diseases Hospital, GTB 
Nagar, Delhi - showed infiltrative lesions were commonly seen in 61.9% 
patients, Extra pulmonary tubercular manifestations were seen in 45.6% 
of HIV-TB. 
 In our study pulmonary tuberculosis was present in 5 out 6 
positive patients (83%). Among these 5 patients, 4 patients having  
Bilateral diffuse in filtration (80%) and one patient having cavity lesion 
(20%). Among 6 patients with HIV positive, one patient have 
Extrapulmonary  Tuberculosis (17%). 
 Calcutta school of Tropical Medicine, Calcutta studied the 
different aspect of human immunodeficiency virus infection and 
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tuberculosis co-infection. Here an out patients department based survey 
conducted in Calcutta and found that all contracted HIV infection by 
hetero sexual route and multiple sex partners. In our study all 6 HIV 
seropositive patients having hetero sexual route was found to be the 
major risk factor for HIV. And all of them having multiple sex partners. 
And one of them also had genital ulcer disease a cofactor facilitating 
HIV transmission. 
 Rajan Babu TB Hospital and infections diseases Hospital GTB 
Nagar, Delhi conducted study of clinical profile of tuberculosis in 
patients with HIV infections / AIDS. Over a period of two years a total 
of 301 tuberculosis patients were suspected to HIV/AIDS coinfection 
and upon testing 42 patients were found to be HIV seropositive. Most of 
the study patients were manual labourers followed by trunk drivers. 
Sexual (hetero sexual) route was found to be the major risk factor for 
HIV / AIDS. The most common symptom in these patients was cough 
with expectration followed by fever and weight loss. 
 In out study all 6 HIV patients are Agriculture Labourers. All 
them having weight loss (100%), five out of 6 patients having cough 
with expectration (83%). Four patient having fever (66%). Three out of 
six patients having chronic diarrhea (50%). 
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PATHOPHYSIOLOGY AND PATHOGENESIS OF HIV 
INFECTION 
 The hallmark of HIV disease is profound immunodeficiency 
resulting primarily from a progressive quantitative and qualitative 
deficiency of the subset of T lymphocytes refered  to helper or inducer T 
cells. This subset has CD 4 molecules on their surface which serve as 
the primary cellular receptor for HIV. A coreceptor must be present 
together with CD4 for efficient fusion and entry of HIV - 1 into its target 
cells. They belong to the seven transmembrance - domain G protein - 
coupled family of receptors. Fusion or CXCR 4 is the coreceptor for T 
cell tropic strains of HIV - 1 and the ß - chemokine receptor CCR 5 is 
the coreceptor for macrophage - tropic strains of HIV - 1. The lymphy 
nodes are the major anatomic sites for the establishment and propagation 
of HIV infection. 
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PRIMARY INFECTION          DESTRUCTION OF  
IMMUNE SYSTEM  
Primary infection 
 
Establishment of Infection in Lymphoid tissue 
 
Massive Viremia 
 
Wide dissemination to Lymphoid organs 
 
HIV Specific 
immune 
response 
 Trapping of virus and establishment of chronic 
persistent infection 
 
  
  Immune activation mediated by cytokines and 
HIV envelope - mediated aberrant cell signaling 
 
  
Partial 
Immunologic 
Control of virus 
replication 
  
  
 Accelerated virus replication 
 
  
 
Rapid CD4+ 
T cell turnover 
  
  
 Destruction of Immune system 
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ESTABLISHMENT OF CHRONIC AND PERSISTENT 
INFECTION 
 HIV infection is relatively unique among human viral infections 
in that, despite the robust cellular and humoral immune responses that 
are mounted following primary infection, the virus is, with very few 
exceptions not cleared completely from the body. Rather a chronic 
infection developments that persists with varying degrees of virus 
replication for a median of approximately 10 years before the patient 
becomes clinically ill. It is this establishment of a chronic infection that 
is the hallmark of HIV disease. HIV has an extraordinary ability to 
mutate. HIV replication occurs throughout the course of HIV infection, 
even during clinical latency (3). 
IMMUNO PATHOGENIC EVENTS DURING CLINICAL 
LATENCY 
 The level of  CD4 + T cells in blood decrease gradually an 
progressively in HIV infected individuals. The slope of this decline 
together with level of the plasma viremia predicts well the pattern of the 
clinical course and the devlopment of advanced disease. Clinical latency 
does not mean disease latency, since progression is generally relentless 
during this period (3). 
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ADVANCED HIV DISEASE 
 After a variable period, usually measured in years, the CD 4 + T 
cell count falls below a critical level ( <200 cells/µ lit) and the patient  
becomes highly susceptible to opportunistic disease. For this reason, the 
CDC case definition of AIDS was modified to include all HIV infected 
individuals with CD 4 + cells counts below this level. The depletion of 
CD 4 + cells continues to be progressive and unrelenting in this phase. It 
is not uncommon for CD 4 + T cell counts to drop as low as 10/µ L or 
even to zero. Patients who progress to this severest forms of immuno 
suppression usually succumb to opportunistic infections or neoplasms. 
T CELL ABNORMALITIES 
 The defects are both quantitative and qualitative and involve 
virtually every limb of the immune system. Virtually all of the immune 
defects in advanced HIV disease can ultimately be explained by the 
quantitative depletion of CD 4 + T cells. One of the first abnormalities 
to be detected is a defect in response to remote recall antigens, such as 
tetanus toxoid and influenza, at a time when mononuclear cells can still 
respond normally to mitogenic stimulation. 
 The level of CD8 + T cells varies throughout the course of 
disease. Following the resolution of acute primary infection, CD 8 + T 
cells generally rebound to higher than normal levels, and they may 
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remain that way throughout the clinically latent stage of the disease. 
This CD 8 + T lymphocytosis may in part reflect the expansion of 
clones of HIV specific CD 8 + CT Lymphocytes. During the later stages 
of HIV infection there is a significant reduction in the numbers of  
CD 8 + T cells. 
INTERACTION BETWEEN M.TUBERCULOSIS AND HIV 
INFECTION 
 The resurgence of Tuberculosis cannot be accounted for entirely 
by the epidemic of HIV infection, although the HIV epidemic clearly is 
a major factor. In addition to the biologic phenomenon of HIV infection, 
socioeconomic conditions such as homelessness, substance abuse and 
increase numbers of persons in institutions are playing an important 
role. 
 The importance of interaction between in Tuberculosis and HIV 
infection relates atleast 5 factors. 
1. There is a high prevalence of tuberculosis in certain HIV 
groups. 
2. Tuberculosis probably is the only HIV related infection that 
is transmitted from  person to person whether or not the 
exposed person is HIV infected. 
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3. If diagnosed promptly and treated appropriately, 
Tuberculosis has a high likelihood of being cured. 
4. Tuberculosis can be prevented in HIV infected populations 
and 
5. Data from several source suggest that tuberculosis may 
accelerate the course of HIV disease. 
Preexisting tuberculosis infection, indicating that endogenous 
reactivation was the dominant if not the only pathogenic mechanism for 
developing tuberculosis. 
There are atleast four factors that influence the rate of 
tuberculosis among cohorts of persons with HIV infection (32). 
1. Prevalence of latent infection with M. Tuberculosis in the 
population. 
2. The likelihood of exposure of the cohort members to 
persons with infectious tuberculosis. 
3. The severity of immune compromise  among cohort 
members and thus, their likelihood of developing active 
tuberculosis if infected with the organism. 
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4. The use of isoniazid preventive therapy by cohort member 
will have an important effect in reducing the incidence of 
tuberculosis. 
Variations among these factors probably account for the 
difference in reported rates of tuberculosis in different cohorts. Cohorts 
consisting largely of middle class homosexual/bisexual men or 
hemophiliacs would be expected to have low rates of Tuberculosis, 
whereas cohorts of injecting drug users living in inner cities would have 
higher rates. Thus, tuberculosis incidence data reported for one cohort 
may not apply to other groups, and there is no single figure that 
accurately defines the risk of tuberculosis in persons with HIV infection 
(32). 
INFLUENCE OF HIV INFECTION ON THE PATHOGENESIS 
OF TUBERCULOSIS 
 Tuberculosis can develop either by direct progression from 
recently acquired infection or by reactivation of latent infection. Cell 
mediated immunity is the predominant mechanism by which a contained 
Tuberculosis is kept quiescent. Because HIV depresses cell mediated 
immunity, the likelihood of reactivation of latent Tuberculous infection 
leading to clinical Tuberculosis is greately increased. 
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MECHANISMS OF CD4 + LYMPHOCYTES DEPLETON & 
DYSFUNCTION (3) 
 HIV mediated direct cytopathicity (Single cell killing). 
 HIV mediated syncytia formation. 
 Virus specific immune responses. 
  HIV specific cytolytic T lymphocytes 
  Antibody - dependent cellular cytotoxicity (ADCC). 
  Natural killer cells. 
 Auto immune mechanisms 
 Anergy caused by inappropriate cell signaling via gp 120/CD4 
interaction Superantigen mediated perturbation of T cell subsets.  
 Programmed cell death (apoptosis). 
 Defect in CD4 + T cell regeneration. 
 In the normal host, once the cell mediated immune response to 
infection with M. Tuberculosis develops, there is a low likelihood that 
new exogenous infection will be acquired. Because of the immune 
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defect inducted by HIV, a person may still be much more vulnerable to 
new infection. Thus, reinfection in persons with HIV infection may 
account for 'relapses' after successful completion of antituberculous 
therapy and also is a mechanism by which multi drug resistance can 
develop. It has been clearly demonstrated that once and HIV infected 
person becomes infected with M. tuberculosis, the infection can 
progress very rapidly to cause clinical disease. In a residential care 
facility for HIV infected persons in San Francisco, Tuberculosis 
occurred within 120 days in 11 of 31 (35%) residents exposed to a 
person with infectious tuberculosis. 
 Presumably because of the pathogenically of M. tuberculosis, 
tuberculosis tends to occur relatively early in the course of HIV 
infection. This is attested to by the findings of several groups that HIV 
seropositive patients with tuberculosis tend to have CD4 lymphocyte 
counts higher than patients with other 'opportunistic' infections like 
pneumocystic carinii pneumonia. In a study of 17 patients, Tuberculosis 
was the initial manifestation of HIV infection in all but two patients, and 
the median CD4 lymphocyte count was 354 / µl. 
 49
DIAGNOSIS OF TUBERCULOSIS INFECTION AND 
TUBERCULOSIS IN HIV INFECTED PATIENTS 
 Tuberculin skin testing 
 Among 94 HIV negative patients 43 patients showed positive 
mantoux test, 51 were negative. All 6 HIV positive patients were 
negative for tuberculin skin test. As would be expected, the tuberculin 
skin test commonly shows little or no reaction in persons with advanced 
HIV infection. However, in earlier stages of the infection, reactivity may 
be maintained. The ability to respond to tuberculin is an indicator of the 
status of cell mediated immunity that in turn is an indicator of the stage 
of HIV infection(32). 
 The prevalence of positive ( > 5 mm induration) tuberculin skin 
test decreased progressively as the CD4 cell count decreased. 
 In a population with a high prevalence of tuberculin reactors, a 
negative tuberculin skin test in an HIV infected person would likely be a 
false negative and that failure to react to the other antigens was a marker 
for severe immune compromise. Thus, such persons would be expected 
to have a high rate of tuberculosis. It would not be expected that this 
high risk of tuberculosis would apply to anergic persons from groups in 
which the prevalence of tuberculin reactivity is low(32). 
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 In addition, the rate of reactivity to mumps and candida skin test 
antigens was related to the CD 4 count. It should be noted, however, that 
the prevalence of anergy was 42% among non-HIV infected injecting 
drug users and 12% among homosexual, bisexual men. These findings 
indicates the elusive nature of the definition and physiologic 
implications of 'anergy' and suggests that this finding should not weigh 
heavily in clinical decision-making. 
 Because of the frequency of blunted skin test responses,or anergy, 
it is recommended by American Thoracic Society and the CDC that a 
reaction of > 5 mm induration to 5 tuberculin unit of purified protein 
derivative be regarded  as indicative of tuberculosis is substantially 
increase in persons with reaction sizes > 5 mm compared with the risk in 
persons with a 1 to 5 mm reactions (32) 
 Anergy testing has been recommended to determine if a negative 
tuberculin test is the result of immunosuppression or is truly negative, as 
well to provide information as to the stage of HIV disease. The antigens 
used include those made from candida organisms, mumps virus, and 
tetanus toxoid to which it is assumed that persons with intact cell 
mediated immunity will respond. But anergy may be found among 
persons who have no identifiable immunosuppression, thus limiting the 
clinical applicability of anergy testing. 
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CLINICAL FEATURES OF TUBERCULOSIS 
 Three HIV positive patients had history of chronic diarrhea. 
 In general examination 5 out of 6 were anaemic. Oral candidiasis 
and hairy leukoplakai were found in two patients. Dirty pigmented large 
tongue was present in one patient. One patient had extensive scabies. 
Hepatomegaly was present in two patient. Tinea versicolar was present 
in two patients and Icthyosis in one patient. 
 This vary considerably in HIV patients depending on the severity 
of the immunosuppression. Presumably because of the virulence of M. 
tuberculosis, tuberculosis may occur early in the course of HIV 
infection. In most series of majority of tuberculosis diagnoses have 
preceded the identification of another AIDS defining disease. 
 It has been shown that the earlier the tuberculosis develops, the 
more 'usual' is its clinical presentation, whereas the latter it occurs, the 
more atypical are its features. Tuberculosis in advanced HIV infection is 
frequently disseminated, has unusual radiographic manifestations and 
non reactive tuberculin skin tests. Lymphnode involvement, inducing 
intrathoracic adenopathy has been described frequently. A retrospective 
study reported a clear associations between low CD 4 cell counts and an 
increased frequency of extrapulmonary tuberculosis and intrathoracic 
adenopathy on chest radiograms. Conversely, pleural effusions were 
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more frequent in person with CD4 cell counts > 200/µl. In this study one 
patient had pleural effusion.  
 Despite the increased frequency of unusual forms of tuberculosis 
in persons with HIV infection, standard, pulmonary disease tends to 
predominate in most series. One of the HIV positive patients had extra 
pulmonary tuberculosis in this study. 
 The clinical picture of TB in HIV + patient differs from in HIV - 
patient following ways: (31) 
Clinical Picture HIV Negative HIV Positive 
Constitutional Symptoms + + Less specific 
Extra Pulmonary disease  0-30% 60% 
Pulmonary disease   
Subapical disease Common Uncommon 
Cavittion 70% 0% 
Lower lobe involvement Rare Common 
Diffuse, Miliary Tuberculosis Rare Common 
Hilar adenopathy Rare Common 
Calcification Common Uncommon 
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RADIOGRAPHIC FINDINGS 
CXR in HIV positive cases 
 Bilateral Diffuse infiltrates - 4 
 Right sided pleural effusion - 1 
 Right upper zone cavity with  
   Bilateral midzone infiltrates - 1 
 
 The atypical findings on chest radiographs of HIV infected 
patients who have Tuberculosis have received considerable emphasis. In 
retrospective studies, features that are not regarded as typical for 
pulmonary tuberculosis have been the norm. Lower lung zone or diffuse 
infiltrations commonly have been observed rather than the usual upper 
lobe involvement. Cavitation has been unusual and intrathoracic 
adenopthay, an unusual finding in immunocompetent adults with 
tuberculosis has been relatively frequent. 
 An evaluation of the radiographic course of treated Pulmonary 
tuberculosis in persons with HIV infection found that, in general, there 
was rapid improvement with little residual scarring after of therapy. 
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BACTERIOLOGIC AND HISTOLOGIC EXAMINATIONS 
 In this study 28 out of 94 HIV negative patients were positive for 
sputum AFB, one out of 6 HIV positive patients was positive. 
 Most reported series indicate that the prevalence of positive 
sputum smears and cultures in patients with pulmonary tuberculosis is 
approximately the same in HIV infected and noninfected persons. 
Potential high yield sources included lymphnodes, bonemarrow, urine 
and blood. In patients with more advanced HIV infection, mycobacterial 
infection does not produce classic granulomas. However, because, 
tuberculosis tends to occur when HIV diseases is less advanced, the 
ability to form granulomas may be intact. Thus, the finding of 
granulomas either in tissue sections or in cytologic preparations from 
needles aspiration biopsies should be interpreted as being more 
consistent with Tuberculosis (32). 
RISK FACTOR ANALYSIS 
 All of 6 patients gave history of extra marital contact. The pattern 
of exposure varied in each patient. 6 patients had multiple contact with 
commercial sex workers. Non of the patients had homosexual contact. 
One patient had previous history of genital ulcer disease. 
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 One person had surgery of haemarroid during which time, had 1 
units of blood transfusion. No other risk factor could be indentified in 
that patients. 
TREATMENT OF TUBERCULOSIS IN THE PRESENCE OF 
HIV INFECTION 
 Most reported series of patients with tuberculosis and HIV 
infection demonstrate a good response to anti tuberculosis treatment 
when regimens containing isoniazid and rifampin are used. Current 
recommendations state that for adult patients with HIV infection, 
treatment for tuberculosis should include isoniazid 300 mg/day, 
rifampin 600 mg per day. Pyrazinamide 20-30 mg/kg/day and 
ethambutol 15 mg/kg/day during the first 2 months of therapy. Isoniazid 
and rifampin should be continued for at least another 4 months, making 
the total duration of therapy at least 6 months. For patients judged to be 
potentially non complaint, therapy should be  given under direct 
observation. This can be facilitated by twice weekly drug administration 
after and initial phase of daily treatment (32). 
 The rate of adverse reactions to antituberculosis drugs is greater 
in persons with HIV infection.They should be followed closely with 
appropriate laboratory and clinical monitoring. There has been no 
systematic evaluation of possible interactions of antibuberculosis drugs 
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with antiretroviral agents. Due to pharmacokinetic interactions, rifabutin 
should be substituted for rifampin in patient receiving the HIV protease 
in hibitors or non-nucleoside reverse transcriptase inhibitors. Both drugs 
should be avoided in patients receving Ritonavir. The antifungal agents 
Ketoconozole and fluconazole both have interactions with isoniazid and 
rifampin resulting in reduction in serum concentrations of the antifungal 
agents. In additional, ketoconazole interferes with absorption of 
rifampicin. Impaired absorption of antibuerculosis drug may also occur 
in patients with HIV infection, presumable as a consequence of 
gastrointestinal disease. For this reason if the response to treatment is 
suboptimal, serum drug concentrations should be measured. The 
incidence of multi drug resistant tuberculosis among HIV patients is 
increasing (32). 
 The ideal ART in the presence of Tuberculosis is 
AZT + 3TC + EFAVIRANZ 
OR 
AZT + 3TC + SAQUINAVIR SGC WITH RITONAVIR BOOSTING 
 The Anti-Tuberculosis treatment could be varied depending on 
the CD4 cell count. 
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CD4 count Drug regimen 
More than 200 Complete Anti TB therapy first and then 
intiate ART therapy 
Between 50 to 200 Intensive phase 
Initial two months - four Anti-TB drug 
therapy 
Continuation Phase 
Subsequent four months - Two Anti TB 
drug therapy. 
+ ART together. 
 
Less than 50 Both ART and above Anti-TB drug therapy 
can be started together 
 
PREVENTION 
 The effectiveness of isoniazid preventive therapy in persons 
infected with both HIV and M. Tuberculosis has been substantiated. In 
addition to the benefit in preventing tuberculosis, it reduces the rate of 
progression to AIDS and also reduces the risk of death. 
 In view of these data, tuberculin testing should be performed as a 
routine part of management forpatietns with HIV infection. Patients with 
reactions of >5 mm should be recommended Isoniazid (300 mg per day) 
prophylaxis for 12 months (32). 
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SUMMARY 
 Among the hundred Tuberculosis patients studied 6 were positive 
for HIV infection. Duration of symptoms in HIV positive patients varied 
from 1 month 10 months. Three of them had chronic diarrhea. 
 Weight loss of more than 20 percent is a consistent finding in all 
the HIV positive patients though it is seen in most of tuberculosis 
patients to a lesser extent. 
 Among 6 HIV positive patients, 5 patients having pulmonary 
Tuberculosis. Extensive Pulmonary Tuberculosis was seen in 4 patients. 
Pleural effusion was seen in one patient. Cavitating lesions were seen in 
only one patient.  
 Hemogram and Erythrocyte sedimentation rat findings were 
similar in HIV positive and HIV negative patients.  They were not 
contributory. 
 Among six human immune deficiency virus positive patients, five 
of them having pulmonary Tuberculosis. In these five patients one 
patient having sputum AFB positive (20%). So confirming the 
diagnosis may require sputum culture. 
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 Mantoux test was not positive (> 5mm) in any of the HIV positive 
patient. It was positive in only 43 of 94 HIV negative patients and it 
could not be depended upon for diagnosis of tuberculosis in both 
groups. 
 One of the HIV positive patients in the study had extra pulmonary 
tuberculosis. 
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CONCLUSION 
  The prevalence of HIV infection among Tuberculosis patients in 
this study is 6%. 
 As Tuberculosis is an early AIDS defining illness, it is mandatory 
to screen all tuberculosis patients for HIV infection and is being 
followed in western countries. 
 Though it is difficult to do the same in our country because of the 
high prevalence of Tuberculosis, prevalence of HIV infection among 
tuberculosis patients is rising. This study has  showed a prevalence of 
6%. 
 Pulmonary Tuberculosis continues to be the dominant form. Only 
one HIV Positive patients had extrapulmonary tuberculosis in this study.  
 The management of tuberculosis patients is not complete if they 
are not screened for HIV in the presence of following features. 
1. Weight loss of more than 20% 
2. History of multiple sexual partners, injection drug abuse, 
blood transfusion, Sexually Transmitted Diseases. 
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3. Atypical chest X-ray findings like lower lobe involvement, 
extensive parenchymal involvement, hilar mediastinal 
lymphadenopathy. 
4. Extrapulmonary tubeculosis 
5. Chronic diarrhea 
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PREVALENCE OF HIV IN TUBERCULOSIS PATIENTS 
PROFORMA 
Name of the Patient :    Ward : 
IP No.   :    DOA : 
Age    : 
Sex    : 
Address   : 
Occupation   : 
SYMPTOMS 
Cough  Duration  
 Productive / Non Productive 
 Quantity 
 Colour 
Haemoptysis  Frequency  
 Amount 
Chest Pain 
Dyspnoea 
Wheeze 
Fever Duration 
 Evening rise of temperature 
Loss of Appetite  Duration 
Loss of Weight Duration  
Diarrhoea Duration 
Abdominal Pain 
Abdominal Distension 
Headache, Neck Pain, Vomiting 
Joint Pain, Back Pain 
Family H/o. TB 
Past H/o. TB 
 Jaundice 
 Diabetes Mellitus 
 Accidents 
 Hospitalisation 
 Previous Surgery 
 Blood Transfusion 
 
Personal History Smoking 
 Alcoholism 
 IV Drug abuse 
Marital Status Married / Unmarried 
Sexual History 
 H/o. Pre / Extra Marital contract Yes  / No 
 Duration 
 Last contract 
 Single / Multiple partners 
 Commercial Sex Worker / Co Worker / Relative / Neighbour 
 Genital Ulcers 
 White Discharge 
 
GENERAL EXAMINATION 
 Weight  
 Height 
 Temperature 
 Anaemia 
 Cyanosis 
 Clubbing 
 Lymphadenopathy 
 Tinea Versicolor 
 Oral Candidiasis 
 Hairy Leukoplakia 
 Kyphosis 
 Scoliosis 
 
 Bp 
 
 Pulse 
 
RESPIRATORY SYSTEM 
 Trachea 
 Apical impulse 
 Chest movement 
 
 Percussion 
 
 Auscultation 
 
CVS 
ABDOMEN  Hepatomegaly 
 Splenomegaly 
 Free Fluid 
 
CNS Neck Stiffnes 
 Spinal Tenderness 
 Fundus 
INVESTIGATIONS 
 
Blood - TC 
 DC 
 ESR 
 Hb% 
 
Mantoux test Size 
Chest X-ray 
 
Sputum AFB 
 
   
   
 
ELISA for HIV 
Rapid test for HIV 
AIDS REFERENCE CENTRE, INSTITUTE OF 
MICROBIOLOGY, MADRAS MEDICAL COLLEGE, CHENNAI. 
 
REQUISITION FOR HIV TEST 
 
Name  Date 
Address 
Age 
Sex 
Occupation  Marital Status 
Probable Diagnosis 
Hosptial  Unit 
 
Clinical Features - Duration  Whether Tested Before 
Date of Testing 
Place of Testing 
Type of Test 
 
ADDITIONAL INFORMATION 
 
H/o. Blood Transfusion : No. of Unit 
  Dateof Last Transfusion 
H/O Surgery 
H/O STD 
H/O MTP 
Last Child Birth 
Whether Spouse Tested 
H/O Multiple Partner Sex Premarital 
 Extramarital 
 
H/O Homosexual Practice 
 
H/O IVD 
 Smoking 
 Alcohol 
 
GENERAL INSTRUCTION 
 
 Assume all blood and body fluids to be potentially hazardous. 
Observe universal safety precautions while collecting blood. Take a 
sterile test tube and place a proper label with name, age, sex and unit. 
 Perform proper skin disinfecting at the venipuncture site 
withdrawn 5 ml of blood and transfer to labeled test tube. 
 Allow to stand for 30 minutes for clot to form and serum to 
separate 
 Transport to the laboratory immediately accompanied by a 
duly filled up request form. 
 if delay is unavoidable, transfer serum into a labeled sterile 
screw capped vial and refrigerate overnight. 
 Transport to laboratory avoiding further delay. 
 S.No. Name Age Sex Duration 
Months 
H/o 
Weight 
loss 
H/o extra 
pulmonary 
symptoms 
Risk factors 
surgery, 
hospitalization 
BL,Transfusion 
IV drug abuse, 
exposure 
Marital 
Status 
STD General 
Examination 
Extrapulm 
involvement 
ESR 
mm/hr 
Total 
Count 
Mantoux 
test 
CXR Diagnosis Sputum 
AFB 
ELISA 
1. VANITHA 27 F 6 + - - M - - - 20 6800 + BUZI B.PTB + _ 
2. SHARMILA 16 F 2 + Neck 
swelling 
- UM - A LN 10 7800 + RUZI PTB 
CTBL 
- - 
3. VADIVEL 30 M 3 + - - UM - - - 68 10200 + RUZFC PTB + - 
4. MOHAMED 25 M 4 + - - M - - - 72 8200 - RPE 
LUZI 
PTB 
RPE 
- - 
5. RANJITHKUMAR 16 M 6 + - - UM - - - 72 9000 + RUZI PTB + - 
6. GLADWIN 36 M 6 + Diarrhea E(M/CSW) M  HM - 58 9200 - BDI PTB + + 
7. GOKUL 18 M 3 + - - UM - - - 82 8000 - RUZI 
RPE 
PTB RPE - - 
8. VEERAMMAL 65 F 3 + - - M - A - 10 7800 - RUZI 
LUZI 
BPTB - - 
9. SARAVANA 37 M 4 + - - M - - - 60 7200 + RUZI PTB - - 
10. VIJI 32 M 7 + - - UM - - - 68 6200 + RUZI PTB + - 
11. LALITHA 25 F 1 + - - UM - A - 20 9200 - RUZI 
LUZI 
BPTB + - 
12. NAGARAJAN 46 M 8 + - - M - - - 72 6400 - RUZI PTB - - 
13. SEKAR 47 M 15 + - - M - - - 25 4800 - MM MTB - - 
14. NOORJAKAN 55 F 1 + - - M - - - 30 7700 + RPE TBPE - - 
15. NARESH 47 M 2 + - - M - - - 28 7800 + RUZI PTB - - 
 
  
S.No. Name Age Sex Duration 
Months 
H/o 
Weight 
loss 
H/o extra 
pulmonary 
symptoms 
Risk factors 
surgery, 
hospitalization 
BL,Transfusion 
IV drug abuse, 
exposure 
Marital 
Status 
STD General 
Examination 
Extrapulm 
involvement 
ESR 
mm/hr 
Total 
Count 
Mantoux 
test 
CXR Diagnosis Sputum 
AFB 
ELISA 
16. KAMALAM 45 F 2 + - - M - - - 32 6400 - BPE BTB PE - - 
17. RAJA 42 M 4 + - - M - - - 28 6000 + LUZI PTB + - 
18. SELVARAJ 56 M 3 + - - M - - - 42 8000 - RUZI PTB - - 
19. MAYAVAN 50 M 3 + - - M - - - 28 6000 + RUZI PTB - - 
20. RAMAN 41 M 3 + - - M - - - 86 8900 + RUZ 
FC 
PTB - - 
21. DHANRAJ 27 M 3 + - - UM - - - 68 6800 - RUZI PTB - - 
22. KAMALA 65 F 3 + - - M - - - 60 4800 + RUZI 
LUZI 
BPTB - - 
23. PATCHIAPPAN 52 M 1 - - - M - - - 62 8000 + RUZI 
RPE 
PTB RPE + - 
24. SIVAKUMAR 26 M 3 + - - UM - - - 38 6500 - RUZI PTB - - 
25. CHINNASAMY 51 M 2 - - - M - - - 62 8000 + RPE RPE - - 
26. THULUKANNAM 60 F 2 - - - M - - - 25 5000 + RUZI 
LUZI 
BPTB + - 
27. MANIKAM 37 M 6 + - - M - - - 58 9600 - RUZI PTB + - 
28. SADHIYA 13 F 3 + - - UM - - - 45 8000 - RUZI PTB - - 
29. VELAN 38 M 3 + - - M - - - 60 6300 - RUZI PTB - - 
30. MOHAN 44 M 4 + - - M - - - 86 4600 - LPE LPE - - 
 
  
S.No. Name Age Sex Duration 
Months 
H/o 
Weight 
loss 
H/o extra 
pulmonary 
symptoms 
Risk factors 
surgery, 
hospitalization 
BL,Transfusion 
IV drug abuse, 
exposure 
Marital 
Status 
STD General 
Examination 
Extrapulm 
involvement 
ESR 
mm/hr 
Total 
Count 
Mantoux 
test 
CXR Diagnosis Sputum 
AFB 
ELISA 
31. RAJESWARI 25 F 4 + - - M - - - 60 8000 + RUZI 
LUZI 
B.PTB - _ 
32. MATHIVANNAN 24 M 4 + SEIZURE - UM - - CNS 62 8100 - RPE TBM RPE - - 
33. VALLIAMMA 35 F 1 - - - M - - - 40 4600 + RUZI 
MZI 
PTB - - 
34. RAJENDRAN 40 M 6 + -  M  - - 60 7000 + RUZI 
MZI 
PTB + - 
35. ELUMALAI 28 M 10 + - E(M.CSW  M - A,OC,HL - 40 7600 - BDI PTB - + 
36. CHINNAMMAL 40 F 4 + - - M - - - 60 5400 - RUZI 
LMZI 
BPTB - - 
37. KAMSALA 27 F 3 + - - M - - - 45 6000 + RUZI PTB + - 
38. RAMESH 21 M 7 + - - UM - - - 56 5600 - RUZI PTB + - 
39. ARUMUGAM 42 M 2 - - - M - - - 28 6800 + RUZI 
MZI 
PTB - - 
40. SAROJA 40 F 2 - - - M - - - 50 6500 + RUZI 
MZI 
PTB + - 
41. SANDOSH 28 M 4 + - - UM - - - 60 7200 - RUZI PTB - - 
42. PADMA 28 F 10 + ABD DIS - M - - ABD 60 6800 + RUZI PTB 
TBAB 
+ - 
43. MURUGAN  39 M 6 + -  M - - - 56 6600 - RUZI PTB - - 
44, VASANDHARAJ 42 M 7 + - - M - - - 40 8000 + LUZI PTB + - 
45. THIRUPURA 
SUNDARI 
50 F 10 + - - M - - - 45 7200 + RUZI 
LUZI 
BPTB - - 
 
  
S.No. Name Age Sex Duration 
Months 
H/o 
Weight 
loss 
H/o extra 
pulmonary 
symptoms 
Risk factors 
surgery, 
hospitalization 
BL,Transfusion 
IV drug abuse, 
exposure 
Marital 
Status 
STD General 
Examination 
Extrapulm 
involvement 
ESR 
mm/hr 
Total 
Count 
Mantoux 
test 
CXR Diagnosis Sputum 
AFB 
ELISA 
46. ELLAMMAL 60 F 1 - - - M - - - 30 6800 + RUZI 
LUZI 
B.PTB - _ 
47. MURALI 32 M 2 - - - UM - - - 54 8100 + RPE 
RUZI 
PTB RPE + - 
48. DEENADYALAN 24 M 6 + - - M - - - 58 7100 - RUZI PTB - - 
49. SURIYAN 42 M 2 + PARA 
PLEGIA 
- M - - SPINE 65 8000 - N TB SPINE - - 
50. GOPAL 44 M 2 + - - M - - - 82 8100 - RPE RPE - - 
51. MANJU 38 F 6 + - - M - - - 30 6800 + RUZI 
MZI 
PTB - - 
52. PERUMAL 30 M 5 + - E(MCSW) M  HM, A, TV - 70 10000 - BPI PTB - + 
53. SAKTHI 40 M 3 + - - M - - - 48 7200 - RUZI PTB - - 
54. DIVIYA 13 F 150 - SEIZURE - UM - - - 60 9000 - N TBM 
TUBER 
- - 
55. ANNAMALAI 38 M 2 - - - M - - - 58 8200 + RUZI PTB + - 
56. GANGA 32 F 6 + - - M - OC, HL - 15 6200 - BDI PTB - + 
57. LALITHA 45 F 3 + - - M - - - 40 5600 + RUZI 
MZI 
PTB + - 
58. PALANIVEL  37 M 1 - - - M - - - 60 8100 + RUZI PTB - - 
59. MURUGAIYA 31 M 2 + - - M - - - 82 6800 - RPE RPE - - 
60. GEETHA 14 F 4 + - - UM - - - 62 8000 - RPE 
RUZI 
- - - 
 
  
S.No. Name Age Sex Duration 
Months 
H/o 
Weight 
loss 
H/o extra 
pulmonary 
symptoms 
Risk factors 
surgery, 
hospitalization 
BL,Transfusion 
IV drug abuse, 
exposure 
Marital 
Status 
STD General 
Examinat
ion 
Extrapulm 
involvement 
ESR 
mm/hr 
Total 
Count 
Mantoux 
test 
CXR Diagnosis Sputum 
AFB 
ELISA 
61. RUCKMANI 60 F 4 + ABD DIS - M - A - 63 8200 + RUZI 
MZI 
PTB 
TB.AB4 
- - 
62. PARVATHI 64 F 2 + - - M - - - 64 8000 - RPE 
RUZI 
PTB RPE - - 
63. NAGAMMAL 65 F 4 + - BT M - A - 84 7200 - RUZI 
LUZI 
BPTB - - 
64. MURUGESAN 29 M 1 + Diarrhea E(M/CSW) M  A, TV, 
DPT, Icty 
- 60 8800 - RUZFC 
BMZI 
BPTB - - 
65. GANESH 25 M 4 + - - UM - - - 56 8000 + RUZI PTB - - 
66. RAJESWARI 37 F ISD - Head ache - M - - CNS 72 68000 - RUZI 
MZI 
PTB TBM - - 
67. SENTHIL 27 M 6 + - - UM - - - 56 6500 - RUZI PTB + - 
68. BALARAMAN 53 M 7 + - - M - - - 65 7000 - RUZI PTB + - 
69. DEVI 55 F 6 + - - M - - - 22 4800 - RUZI PTB - - 
70. RAVI 40 M 2 + - - M - - - 72 6800 + RUZI 
MZI 
PTB - - 
71. BABU 40 M 1 - - - M - - - 25 8000 - MM MTB - - 
72. IBRAHIM 30 M 1 + - - UM - - - 68 8200 - R 
Pneumo 
R Pneumo - - 
73. VENTESH 54 M 3 + - - M - - - 68 7100 - RUZI PTB - - 
74. KARTHIKEYAN 26 M 4 + - - UM - - - 72 6100 - RUZI PTB - - 
75. JANETRANI 13 F 200 - Cervical 
adeno 
pathy 
- UM - - LN 72 8000 + RUZI 
MZI 
PTB CTBL + - 
 
 
  
S.No. Name Age Sex Duration 
Months 
H/o 
Weight 
loss 
H/o extra 
pulmonary 
symptoms 
Risk factors 
surgery, 
hospitalization 
BL,Transfusion 
IV drug abuse, 
exposure 
Marital 
Status 
STD General 
Examination 
Extrapulm 
involvement 
ESR 
mm/hr 
Total 
Count 
Mantoux 
test 
CXR Diagnosis Sputum 
AFB 
ELISA 
76. KANNIGA 35 F 20D - SEIZURES - M - A CNS 40 9600 + N TBM - _ 
77. VEERASAMY 48 M 3 + - - M - - - 40 6000 - MM MTB - - 
78. MUTHURAJ 32 M 10 + DIARRHOEN EMCSW UM - A Scabics - 44 8600 - RPLE RPE - + 
79. DOSS 57 M 4 + - - M - - - 30 6300 - RUZI PTB + - 
80. CHITRA 25 F 15D - Seizures - UM - - CNS 60 13200 - RUZI PT TBM - - 
81. MARY 40 F 3 + - - M - - - 15 4600 - RUZI 
LUZI 
BPTB + - 
82. MUNIANDI 32 M 3 + - - M - - - 42 7400 + RUZI PTB - - 
83. SINGARAJ 29 M 4 + - - M - - - 38 6600 - RUZI PTB - - 
84. MASILAMANI 52 M 4 + - - M - - - 42 4800 + LUZI PTB + - 
85. SALAMMAL 56 F 1 + - - M - A - 25 7500 - MM MTB - - 
86. SIVASHANKAR  30 M 5 + - - UM - - - 62 6300 - RUZ 
FC 
PTB - - 
87. SHANKAR 40 M 2 + - - M - - - 68 9400 + RUZI PTB + - 
88. SHANDHA 45 F 6 + - - M - - - 12 4600 + RUZI 
MZI 
PTB + - 
89. RAJA 44 M 3 + - - M - - - 62 9000 - RUZ 
FC 
PTB - - 
90. ALAMELU 26 F 2 + ABDOMI 
NAL 
DISTENTION 
- M - A ABDOMEN 13 6500 + LUZI PTB TB 
ABD 
- - 
 
  
S.No. Name Age Sex Duration 
Months 
H/o 
Weight 
loss 
H/o extra 
pulmonary 
symptoms 
Risk factors 
surgery, 
hospitalization 
BL,Transfusion 
IV drug abuse, 
exposure 
Marital 
Status 
STD General 
Examination 
Extrapulm 
involvement 
ESR 
mm/hr 
Total 
Count 
Mantoux 
test 
CXR Diagnosis Sputum 
AFB 
ELISA 
91. SOUNDARAMMA 40 F 3 + - - M - - - 62 5000 - RE 
LUZI 
PTB RPE - _ 
92. SURESH 27 M 3 + - - UM - - - 68 9700 - RUZI 
MZI 
PTB - - 
93. DHANABAL 60 M 4 + - - M - - - 58 4600 + RPE RPE - - 
94. RAGUNATHAN 55 M 3 + - - M - - - 60 8100 + RUZI 
LUZI 
BPTB + - 
95. SAROJA 45 F 6 + - - M - - - 26 7100 + RUZI 
MZI 
PTB - - 
96. JOHN 52 M 3 + - - M - - - 42 7800 - RPE TB RPE - - 
97. KAMARUDEN 47 M 6 + - - M - - - 62 6000 + RUZI 
MZI 
PTB - - 
98. SHANKAR 36 M 3 + - - M - - - 42 8000 - RPE TB RPE - - 
99. NALINI 24 F 2 + - - UM - - - 56 8100 - RUZI 
MZI 
PTB - - 
100. KAMATCHI 40 F 4 + - - M - - - 60 8000 - RUZI PTB + - 
 
  
DESCRIPTION OF POSITIVE CASES 
 
Sl.No. I.P.No. Age Sex Duration of 
symptoms months 
Extra pulm 
Symptoms 
Risk 
factors 
Marital 
Status 
Clinical 
marker 
ESR 
(mm/hr) 
Total 
Count 
CXR MX AFB 
1. 768958 36 M 6 Diarrhea E(M/CSW) M HM 58 9200 BDI -Ve +Ve 
2. 762935 28 M 10 - E(M/CSW) M A, OC, HL 40 7600 BDI -Ve -Ve 
3. 786920 30 M 5 - E(M/CSW) M HM, A, TV 70 10,000 BDI -Ve -Ve 
4. 778643 29 M 1 Diarrhea E(M/CSW) M TV,ICY,A,DPT 60 8800 RUZFC/
BMZI 
-Ve -Ve 
5. 743202 32 F 6 - E (M) M OC-HL 150 10000 BDI -Ve -Ve 
6. 776714 32 M 10 Diarrhea E (M/CSW) 
GU 
M A,TV, scabies 44 8800 RT, 
PLEF 
-Ve -Ve 
 
I.P.No. - In Patient Number   ICY - Iethyosis  DPT - Dirty Pigmented tongue  BDI - Bilateral Diffuse Infiltrates 
E - Exposure  UM - Unmarried  OC - Oral Candidiasis  PLEF - Pleural Effusion 
S - Single  M - Married  HL - Hairy Leukoplakia     
M - Multiple  HM - Hepatomegaly  CXR - Chest X-ray     
CSW - Commercial Sex Worker  A - Anaemia  UZ - Upper Zone     
GU - Genital Ulcer  TV - Tinea Versicolar  MZ - Mid Zone     
 
 ABBREVIATIONS USED IN MASTER CHART 
 
 
STD - Sexually Transmitted Diseases UZ - Upper Zone 
ESR - Erythrocyte Sedimentation rate MZ - Mid Zone 
CXR - Chest X - ray LZ - Lower Zone 
AFB - Acid Fast Bacilli I - Infiltrate 
D - Days D - Diffuse 
CNS - Central Nervous System PE - Pleural Effusion 
J - Jaundice C - Cavity 
M - Multiple N - Normal 
CSW - Commercial Sex Worker Pneumo- Pneumothorax 
TBM - Tuberculous Meningitis  
  
Martial Status  
M - Married MTB - Miliary Tuberculosis 
UM - Unmarried DPT - Dirty Pigmented Tongue 
A - Anaemia HL - Hairy LEUkoplakia 
TBAB - Tuberculour Abdomen B - Bilateral 
L - Lymphadenopathy R - Right 
TV - Tinea Versicolar L - Left 
CTBL - Cervical TB Lymphadenitis MM - Miliary Mottling 
HM  Hepatomegaly OC - Oral Candidiasis 
 
SPUTUM AFB
70
30
Negative Positive
MANTOUX TEST
57
43
Negative Positive
HIV
94
6
Negative Positive
Negative Positive
70 30
Negative Positive
57 43
Negative Positive
94 6
 HIV POSITIVE PATIENT -  
EXTENSIVE PULMONARY TUBERCULOSIS 
 HIV POSITIVE PATIENT -  
RIGHT PLEURAL EFFUSION 
 HIV POSITIVE PATIENT -  
EXTENSIVE PULMONARY TUBERCULOSIS 
 HIV POSITIVE PATIENT -  
RIGHT MULTIPLE CAVITIES 
 HIV NEGATIVE PATIENT-  
RIGHT UPPER ZONE CAVITY 
  
HIV NEGATIVE PATIENT -  
RIGHT PNEUMOTHORAX, BEFORE 
INTERCOSTAL DRAINAGE 
HIV NEGATIVE PATIENT -  
RIGHT PNEUMOTHORAX,  
AFTER INTERCOSTAL DRAINGAGE 
